Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study (Q34452266)

2 August 2017

Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study (English)

1 reference

2 August 2017

0 references

0 references

1 reference

Hoffmann J

1

1 reference

PubMed ID

9428831

2 August 2017

Spengler M

series ordinal

2

1 reference

PubMed ID

9428831

2 August 2017

language of work or name

English

0 references

publication date

1 December 1997

1 reference

American Journal of Medicine

2 August 2017

1 reference

2 August 2017

103

1 reference

2 August 2017

483-490

1 reference

2 August 2017

6

1 reference

Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900252-0

Metabolic effects of metformin in non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900252-0

Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900252-0

Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900252-0

The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900252-0

Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900252-0

Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900252-0

Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900252-0

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900252-0

A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900252-0

The pharmacological treatment of hyperglycemia in NIDDM. American Diabetes Association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900252-0

The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900252-0

Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900252-0

Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900252-0

Insulin and Cardiovascular Disease: Paris Prospective Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900252-0

Risk factors for early death in non-insulin dependent diabetes and men with known glucose tolerance status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900252-0

Insulin resistance and insulin deficiency in the pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus: errors of metabolism or of methods?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900252-0

Insulin and atherosclerosis: villain, accomplice, or innocent bystander?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900252-0

Why is insulin not a risk factor for coronary heart disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900252-0

Associations between insulin levels and cardiovascular disease are confounded by comorbidity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900252-0

Is insulin really a heart disease risk factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900252-0

Hypertension and associated metabolic abnormalities--the role of insulin resistance and the sympathoadrenal system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900252-0

Persistent elevation of plasma insulin levels is associated with increased cardiovascular risk in children and young adults. The Bogalusa Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900252-0

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900252-0

Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900252-0

Plasma triglycerides and three lipoprotein cholesterol fractions are independent predictors of the extent of coronary atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900252-0

A prospective study of the effect of 12 months treatment on serum lipids and apolipoproteins A-I and B in Type 2 (non-insulin-dependent) diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900252-0

Comparison of tolbutamide and metformin in elderly diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900252-0

Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900252-0

10.1016/S0002-9343(97)00252-0

7 January 2021

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

9428831